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Polyurethanes (PU) are polymers made from diisocyanates and polyols for a variety of consumer prod-
ucts. It has been suggested that PU foam may contain trace amounts of residual toluene diisocyanate
(TDI) monomers and present a health risk. To address this concern, the exposure scenario and health risks
posed by sleeping on a PU foam mattress were evaluated. Toxicity benchmarks for key non-cancer end-
points (i.e., irritation, sensitization, respiratory tract effects) were determined by dividing points of
departure by uncertainty factors. The cancer benchmark was derived using the USEPA Benchmark Dose
Software. Results of previous migration and emission data of TDI from PU foam were combined with con-
servative exposure factors to calculate upper-bound dermal and inhalation exposures to TDI as well as a
lifetime average daily dose to TDI from dermal exposure. For each non-cancer endpoint, the toxicity
benchmark was divided by the calculated exposure to determine the margin of safety (MOS), which ran-
ged from 200 (respiratory tract) to 3  106 (irritation). Although available data indicate TDI is not carcin-
ogenic, a theoretical excess cancer risk (1  107) was calculated. We conclude from this assessment that
sleeping on a PU foam mattress does not pose TDI-related health risks to consumers.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Polyurethanes (PU) are polymers made by reacting diisocya-
nates (monomers with two isocyanate (NCO) groups) with polyols
or chemically related compounds (Fig. 1). These polymers are man-
ufactured in industrial settings for subsequent use in consumer
products such as furniture, automotive interiors, bedding, carpet
underlay, insulation and coatings. It is thought that any NCO
groups present in the PU foam following curing are attached toDS, USEPA benchmark dose softwa
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-NC-ND license.large molecular weight heterogenous polymers that prevents their
release by either evaporation or diffusion (Vangronsveld et al.,
2012). The levels of attached NCO groups decline rapidly, probably
by reacting with ambient atmospheric moisture (Cole et al., 1987).
Fully cured PU products are considered toxicologically inert (USEP-
A, 2011a) since they contain neither unreacted TDI nor biologically
available NCO groups (Dieterich et al., 1993).
Despite these generally held beliefs, there are reports that unre-
acted TDI is present in cured PU foam. Gagné et al. (2003) andre; CSF, cancer slope factor; FEV, forced expiratory volume; FEV1, forced expiratory
DD, lifetime average daily dose; LMS, linearized multistage; LLNA, local lymph node
detection limit; NTP, national toxicology program; NESIL, no expected sensitization
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Fig. 1. Generic reaction of TDI with a polyol to form a polyurethane.
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‘‘free TDI’’ (i.e., residual unreacted TDI monomer) in PU products,
even after prolonged aging. However, the presence of free TDI is
unlikely. The absence of TDI emissions [limit of detection (LOD)
of 0.2–0.5 ng/g] from PU foam spiked with TDI (Hugo et al.,
2000) suggests that results reported by Gagné et al. (2003) are
likely due to either degradation of the foam by the extraction pro-
cedure and/or reaction of the derivatization agent with other
extractable, low-molecular weight components (e.g., oligourea) in
the foam. In addition, the reliability of the Krone et al. (2003) re-
sults have been questioned based on the absence of both control
samples and the positive identiﬁcation of isocyanates, use of di-
methyl sulfoxide as solvent, and the unusual ratios of putative
TDI isomers in different samples (Cleet, 2005). The TDI commonly
used in foam manufacture is an isomer mixture of 2,4- and 2,6-TDI
(80:20). Toxicity tests have predominantly been performed on this
isomer mixture, and in this manuscript TDI is used to refer gener-
ically to the isomer mixture or single isomers.
While few concerns are expressed about the safety of PU foams,
this assessment quantitatively addresses the concern that unre-
acted TDI monomer may escape from the polymer matrix and pose
a health risk. Sleeping on a PU foam mattress was the exposure
scenario selected for this assessment since it represents a situation
that would accentuate the potential for consumer exposure.2. Methodology
It is generally accepted that risk assessment can be performed





Risk is a function of both toxicity (hazard and dose–response)
and exposure. The sections below detail the risk assessment pro-
cess for TDI. By combining appropriate analytical data and expo-
sure modelling with the toxicity benchmarks provided herein,
similar risk characterizations can be made for other TDI-based
PU products.2.1. Toxicity assessment
Toxicity refers to the inherent property of every chemical to
cause adverse health effects at some level of exposure. It can be
determined by evaluating responses in experimental animals ex-
posed to chemicals under deﬁned laboratory conditions (most
commonly) or in humans exposed to chemicals in their environ-
ment. Traditionally, toxic effects have been broadly divided into
non-cancer and cancer endpoints. In this document, only toxicity
endpoints relevant to TDI (i.e., skin irritation; skin sensitization;
respiratory sensitization; lung irritation and decrement not related
to asthma; and carcinogenicity) are considered. Dose–response
data on the potential adverse health effects from TDI in PU prod-
ucts are likely the same as that for the monomer itself. Comprehen-
sive information about the toxicity of TDI monomer is available invarious reviews or agency documents (Bolognesi et al., 2001; Cana-
dian Government, 2008; Collins, 2002; ECHA, 2011; European
Commission Joint Research Centre, 2000; IARC, 1999; National Re-
search Council, 2004; Ott, 2002; USEPA, 1995).
For non-cancer endpoints, toxicity benchmarks were identiﬁed
by dividing each point of departure (POD) by a combined uncer-
tainty factor. PODs (e.g., No Observed Adverse Effect Level, NOAEL)
were selected following a review of relevant dose–response data
for each endpoint. Combined uncertainty factors were calculated
as the product of two or more factors that compensate for uncer-
tainties associated with the POD (e.g., inter- and intra-species var-
iability, extrapolation from less than lifetime-to-lifetime exposures
and weakness of the toxicological database). Uncertainty factors
were derived from regulatory and other expert guidance and
reﬁnements to these factors based on the toxicological database
for TDI. For cancer, the cancer slope factor (CSF) was derived using
the USEPA Benchmark Dose Software (BMDS) (http://www.epa.-
gov/ncea/bmds/dwnldu.html) version 2.2 and the USEPA preferred
linearized multistage (LMS) cancer model to describe the relation-
ship between risk and dose below the experimentally observed
range. The CSF is deﬁned as the upper 95% conﬁdence limit on
the slope of the risk–dose relationship with units of risk per mg/
kg bw/day.2.2. Exposure assessment
Exposure is a function of the mass of material in contact with
the body as well as the exposure conditions under which contact
occurs. In the case of dermal irritation and sensitization where
contact alone is a key parameter, the appropriate dose-metric is
mass per unit area (European Commission, 2010; Kimber et al.,
2008; Loveless et al., 2010). Otherwise, exposures are commonly
expressed in units of mg/kg bw/day, the amount of material con-
tacted (mg) per mean body weight (kg) of the subject per unit of
time (day). Exposures can be measured empirically or modelled
based on the physical–chemical properties of the chemical, physi-
ological characteristics of the receptor population (e.g., absorption
rate, inhalation rate, body weight), and contact conditions (i.e., fre-
quency, duration, and route) for the exposure scenario under
study. Selected exposure variables typically represent a combina-
tion of average and upper-bound values designed to estimate the
exposure experienced by individuals at the upper end (e.g., 90th
percentile) of the exposure distribution. A common exposure met-
ric for cancer endpoints is the Lifetime Average Daily Dose (LADD).
If there were to be human exposure to TDI monomer from PU
products, in principle it would be most likely to occur via inhala-
tion (release of TDI to air) and dermal contact (transfer of TDI to
the skin). One scenario which would provide maximal opportunity
for such exposure via these routes would be sleeping on a ﬂexible
PU foammattress. A high index (119) PU foamwas selected for this
assessment. The index refers to the stoichiometric ratio of TDI to
polyol used to manufacture the foam, with a value of 100 indicat-
ing equal amounts of TDI and polyol. The index of commercial PU
foam bedding typically ranges between 105 and 115. The high in-
dex PU foam used for this assessment was conservatively selected
to represent PU foammost likely to contain residual unreacted TDI.
The magnitude of other potential TDI exposures (e.g., ingestion of
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considered herein as they are expected to be relatively minor
routes of exposure; in contact with traces of water, TDI would
polymerize forming polyurea (Mormann et al., 2006).
2.2.1. Dermal exposure
The amount of TDI available for dermal exposure during sleep
was based on results from migration studies by Vangronsveld
et al. (2012). In this study, migration of TDI was determined by
placing a migration collection system (i.e., ﬁlter paper disks
impregnated with a TDI trapping agent) in contact with the surface
of PU ﬂexible foam, then clamping the foam/migration collection
assembly together (foam compression 25% by height) for periods
of either 8 or 24 h. At the end of the test period, the cell was disas-
sembled, and the migration collection system was analyzed for
TDI.
2.2.2. Inhalation exposure
The TDI concentration in air during a sleep period was deter-
mined based on results from emission studies by Vangronsveld
et al. (2012). These studies were carried out on PU ﬂexible foam
using three different emission cells – the FLEC cell, the micro-
chamber (l-CTE™) and a ﬂow through cell. The TDI emitted to
the air passing through each test cell was measured using a glass
ﬁber ﬁlter impregnated with a TDI trapping agent. Both the FLEC
cell and l-CTE™ are used by commercial product emission testing
laboratories and have been referenced by international standard
methods for emission testing (i.e., prENV 13419-2, ISO/DIS
16000-10, ASTM 7143-05). The FLEC cell was determined to be
the most appropriate for the derivation of the inhalation exposure
concentration since it afforded the most sensitive measurement of
emitted TDI.
2.3. Risk characterization
The assessment of risk depends on the type of adverse health ef-
fect. For non-cancer effects, a general approach is to divide the tox-
icity benchmark by the calculated exposure value to derive a
Margin of Safety (MOS). The target MOS is 1 since the associated
uncertainty factors (e.g., inter- and intra-species variability) are in-
cluded within the derivation of the toxicological benchmark. For
clarity, this term is different than the term ‘‘Margin of Exposure’’
(MOE), which is deﬁned in this context as the ratio of the POD
(such as a NOAEL) and the estimated exposure dose or concentra-
tion. The target MOE then reﬂects the magnitude of the uncertainty
factor(s) associated with the particular toxicological endpoint. For
genotoxic carcinogens, regulatory agencies conservatively assume
that cancer risks exist below the experimentally derived NOAEL
(i.e., there is no threshold) and approach zero only when exposures
do. To address potential cancer concerns, the LADD was multiplied
by the CSF for TDI to determine an upper bound on the excess can-
cer risk for a lifetime of sleeping on a foam mattress and the prod-
uct was compared to the acceptable excess cancer risk of 106
commonly targeted by regulatory agencies for the general
population.1 EC3 is deﬁned as the concentration leading to a threefold increase of the baseline




Studies in rabbits have reported that TDI produces moderate
dermal irritation when applied to intact or abraded skin (Duprat
et al., 1976; Knapp and Baker, 1974). In a mouse Local Lymph Node
Assay (LLNA) examining the dermal sensitization potential of TDI,Woolhiser et al. (1998) reported irritation at the TDI application
site. Other rabbit and mouse studies have reported variable results
ranging from slight irritation (Wazeter et al., 1964) to corrosion
(unpublished study by Suberg et al., 1984). While in isolation these
studies are insufﬁcient to characterize the dermal irritation poten-
tial of TDI due to the lack of documentation and use of non-stan-
dard methodology, the overall weight of evidence indicates that
TDI is irritating to the skin of experimental animals.
Studies in humans (Daftarian et al., 2002; Huang et al., 1991)
have reported skin effects associated with occupational exposures
to TDI. While it is often unclear if the skin effects are attributable to
primary irritation or sensitization, there is a suggestion that irri-
tant dermatitis is more common than allergic contact dermatitis
(Daftarian et al., 2002). In subjects with occupational skin disease,
approximately 2% of the 360 patients investigated showed evi-
dence of skin irritation when 15 mg of a 1.5% or 2% TDI solution
was applied to the skin for two days (Kanerva et al., 1999). Given
the test chamber area (50 mm2), a 1.5% solution corresponds to a
skin exposure of 600 lg TDI/cm2. This value is considered the Low-
est Observable Adverse Effect Level (LOAEL) and is divided by a
combined uncertainty factor of 3 to derive a NOAEL of 200 lg
TDI/cm2 for human skin irritation. The combined uncertainty fac-
tor is based on a factor of 3 for LOAEL to NOAEL conversion and
a factor of 1 for intraspecies variability. The former reﬂects the ex-
treme exposure conditions (i.e., two days contact under occlusive
dressing), the low incidence of irritation observed by Kanerva
and coworkers, as well as the lack of human skin irritation reported
by others. An intraspecies factor of 1 reﬂects the fact that the
LOAEL was derived from a relatively large group of potentially sen-
sitive individuals attending a clinic for skin problems.
3.1.2. Skin sensitization
The complexities of skin sensitization thresholds are not well
understood making it difﬁcult to assess the relevance of the com-
paratively low thresholds to TDI seen in animals to the apparently
high thresholds predicted by human experience. The no observed
effect level (NOEL) for the induction of sensitization derived from
animal models appears to be lower than that in humans. Behind
this observation are extreme exposure conditions associated with
animal protocols and the absence of well documented cases of skin
sensitization in the workplace. This contention is consistent with
the animal and human data summarized below.
In animals, TDI is a well recognized skin sensitizer (Auletta,
1984; Duprat et al., 1976; Hilton et al., 1995; Karol et al., 1981;
van Och et al., 2000; Thorne et al., 1987; Woolhiser et al., 1998;
Zissu et al., 1998). Two studies that followed guideline methodol-
ogies and included dose–response information were those by Aul-
etta (1984) and Hilton et al. (1995). Auletta (1984) performed a
dose–response sensitization study in Guinea pigs. While irritation
was observed at an induction dose of 30 mM TDI (0.52% weight/
volume), sensitization reactions were not seen at any challenge
dose, demonstrating a NOEL for induction. Laboratory experience
suggests that the topical application of 50 ll can cover up to
15 cm2 of skin. Thus, the NOEL of 30 mM in Guinea pigs corre-
sponds to a dermal sensitization threshold of about 17,000 ng/
cm2. Hilton et al. (1995) determined an EC3 of 0.02% (w/v)1 for der-
mal sensitization using the mouse LLNA, which has emerged as a
preferred method for sensitization testing due to the pragmatic
and scientiﬁc advantages it affords (Loveless et al., 2010). Based on
the LLNA protocol (i.e., 25 ll applied to 1 cm2 of skin on each ear),
the EC3 of 0.02% corresponds to a dermal exposure of 5000 ng TDI/
cm2.
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sidered rare and has been associated with poor workplace hygiene
(Huang et al., 1991). In a ﬂexible foam plant, 26 TDI exposed work-
ers reporting skin symptoms underwent patch testing with a 2%
TDI solution, none developed a reaction to the TDI antigen (Daftar-
ian et al., 2002). In addition, only 1% of dermatology patients with a
suspected sensitivity to diisocyanates demonstrated an allergic
skin reaction to TDI (Liippo and Lammintausta, 2008). In a series
of 360 dermatology patients skin tested for ACD to plastics and
glues, 1.5 or 2% TDI (i.e., 4.5  105 ng/cm2 or 6  105 ng/cm2)
was found to elicit an allergic response in only 0.8% of cases
(Kanerva et al., 1999). This study provides prevalence rates for a
dermatology clinic population, where patients were tested for
occupational skin disease using a modiﬁed European series that in-
cluded a panel of 26 standard allergens (Bruynzeel et al., 1995) and
20–30 other compounds relevant to their work and hobbies. As the
standard series itself is expected to have false positive rate of at
least 5% (Nethercott, 1990), the prevalence of 0.8% for TDI does
not indicate a meaningful level of TDI skin sensitization in this
cohort.
A number of approaches have been advanced in recent years
(e.g., ECETOC, 2008; ECHA, 2010; Felter et al., 2003; Griem et al.,
2003; Kimber et al., 2001; Safford, 2008) that use relative potency
data (i.e., EC3) obtained from mouse LLNA studies to derive a ‘‘no
expected sensitization induction level’’ (NESIL). Different features
of these approaches are described in Table 1. Aside from common
uncertainty factors that account for interspecies and intraspecies,
these approaches take into consideration factors that are more spe-
ciﬁc to dermal exposure and sensitization testing. Taking these ap-
proaches into consideration for the current PU foam scenario, a
benchmark toxicity value (NESIL) for the general population of
333 ng/cm2 was derived by dividing the NOEL (EC3) of 5000 ng/
cm2 by a total uncertainty factor of 15 that was based on multiple
considerations. The LLNA appears to be a sensitive indicator of der-
mal sensitization potential relative to human experience, and a fac-
tor of 3 was used to account for potential interspecies variability in
the EC3 value. In addition, despite the rarity of skin sensitization in
humans, a factor of 5 was selected for intraspecies variability to ac-
count for potential uncertainties associated with the human devel-
opment of and predisposition to ACD. A factor of 1 was selected for
matrix effects since the availability of TDI in acetone:olive oil
(LLNA) is likely greater than that of TDI, which must passively mi-
grate through multiple molecular barriers (e.g., fabric, sweat) be-
fore contacting the skin. Factors that might be used to reﬂect
enhanced penetration, longer exposure, dermal integrity, or occlu-
sive exposure are not applicable to the scenario of sleeping on a
mattress. Uncertainty factors of 1 were assigned for considerations
such as data quality, dose–response proﬁle, and reliability (ECHA,
2010) since the LLNA data were reported in a peer-reviewed pub-
lication from a reliable laboratory and were supported by similar
data from other investigators. The calculated NESIL value is judged
conservative given the relatively rare induction of ACD to TDI in
humans. The discrepancy between the animal data and human
experience must be considered when evaluating their respective
relevance for risk assessment.
3.1.3. Respiratory sensitization
The ability of TDI to induce respiratory sensitization in suscep-
tible individuals is a known adverse health effect in humans. While
various animal models (i.e., induction by inhalation or dermal
exposures) have been constructed that measure respiratory re-
sponses (i.e., immediate-onset and/or delayed-onset) following
an inhalation challenge with TDI (e.g., Botham et al., 1988; Karol,
1983; Pauluhn and Mohr, 1998), there is still no validated model
that adequately reﬂects the respiratory sensitization process and
response in humans. In particular, the role that dermal contactwith TDI plays in the development of respiratory sensitization re-
mains an open question. Data on this issue have been considered
(Graham et al., 2002) and it was concluded that while animal
and human data suggest the immune system can be activated by
topical exposures to TDI, it is unclear whether dermally-mediated
activation is sufﬁcient to initiate respiratory sensitization in hu-
mans. Given this mechanistic uncertainty, as well as the absence
of clinical data demonstrating that TDI skin exposures lead to an
asthmatic response, this assessment focuses on only the potential
risk of respiratory sensitization induced by the inhalation of TDI.
Data in animals and humans relevant to this topic are presented
below. Although dose–response relationships are not clearly iden-
tiﬁed, the limited data indicate that the induction of respiratory
sensitization is a threshold phenomenon, although the NOEL is
dependent on the data set examined.
The induction of respiratory sensitization was evaluated by
exposing Guinea pigs (head only) to TDI vapor at concentrations
of 20 ppb for 70 days or 120–7600 ppb for a week followed by an
inhalation challenge with TDI–guinea pig serum albumin conju-
gates (TDI–GSA) (Karol, 1983). Respiratory responses were evalu-
ated by measuring increases in respiratory rate and antibody
production after challenge with 1% TDI–GSA. The NOEL for induc-
tion was 120 ppb TDI based upon antibody production. Using a
mouse model, Matheson et al. (2005) reported respiratory tract re-
sponses following the daily inhalation of 20 ppb TDI for 6 weeks.
After a two week non-exposure period, animals were challenged
via inhalation to 20 ppb TDI for 1 h. TDI-treated mice demon-
strated enhanced airway inﬂammation and some hyperreactivity
to methacholine (PENH), elevated IgE and IgG antibody levels,
and increased Th1/Th2 cytokine expression in lung tissue. These
responses support a LOEL for induction of 20 ppb in this mouse
model.
Many clinical and epidemiologic studies have been carried out
since 1950 in order to evaluate the risk of developing occupational
asthma. Recent studies have shown a downtrend in the global and
regional incidences of occupational asthma in general and of isocy-
anate related asthma in particular since the 1990s (Bakerly et al.,
2008; Buyantseva et al., 2011; Paris et al., 2012; Vandenplas
et al., 2011), perhaps indicative of the increasing emphasis on
workplace exposure controls. In a large Canadian study of 223
companies using diisocyanates between 1984 and 1988 (Tarlo
et al., 1997), the calculated overall annual incidence of occupa-
tional asthma was higher (0.7%) for companies with at least one
case of occupational asthma and time-weighted-average (TWA)
concentrations >5 ppb than for all potentially exposed employees
(0.2%) of the companies under study (Ott et al., 2003). Detailed re-
views (Ott, 2002 and Ott et al., 2003) have also shown an associa-
tion between the declining incidence of diisocyanate asthma and
decreasing levels of airborne TDI in the workplace. However, even
in workplaces with TWA TDI concentrations below 5 ppb, short-
term concentrations exceeded 20 ppb during some work activities
and occasionally exceeded 80 ppb (Ott et al., 2003). These high
short-term exposures may explain the cases of diisocyanate asth-
ma seen with TWA TDI concentrations below 5 ppb, since studies
with detailed exposure data indicate that high, short-term expo-
sures to TDI can lead to respiratory sensitization (Bugler et al.,
1991; Ott et al., 2000; Weill et al., 1981). This hypothesis is consis-
tent with the occupational experience that respiratory sensitiza-
tion does not occur when concentrations of 5 ppb and below are
maintained (DFG, 2003; Diller, 1998). In a review of the critical
data for the TDI OEL, it was stated that ‘‘If the exposure concentra-
tions of TDI are kept below 10–20 ppb, generally no new cases of
TDI asthma are observed’’ (AGS, 2006). These considerations have
led to the acceptance of 5 ppb (8-h TWA) and 20 ppb (short term
limit) by many regulatory authorities for control of occupational
exposures to TDI.
Table 1
Uncertainty factor scheme for the dermal sensitization endpoint.









Felter et al. (2003) TDI-PU ﬂexible foam




Log10 NESIL lg/cm2 = 1.16




EC3 lower bound potency
classiﬁcation  default
NOAEL
3 (EC3  NOAEL,
Variability = 3)
Intraspecies (variability) 5–10 10 10 10 10 5 (occurrence rare,
variability low)
Matrix 1–10 <1–10 1–10 – 1–10 1 (acetone: stringent
conditions)
Case-by-case exposure conditions
(repeated, duration, dermal integrity,
humidity, product use)
10 1–10 1–10 10 1–10 n/a
Dose–response, reliability 1–10 – – – – 1
Data quality 1–10 – – – – 1
Typical total UF (assumes quality data) 500–1000 100 100–400 300 100 15
EC3 is deﬁned as the concentration leading to a threefold increase of the baseline lymph node cell proliferation in the LLNA using thymidine labeling (Kimber et al., 2001).
DST – dermal sensitization threshold & TTC – threshold of toxicological concern.
NESIL – no expected sensitization induction level.
ANSAD – acceptable non-sensitizing area dose & ANEAD - acceptable non-eliciting area dose.
NOAEL = No observable adverse effect level.
LOAEL = Lowest observable adverse effect level.
a ECHA TGD Appendix R.8-10. EC3 data generally correlate well with human skin sensitisation thresholds derived from historical predictive testing; however, there are
cases where this correlation is poor and the two values may differ by 10-fold or more. In view of this variation, the default AF of 10 for interspecies variation (see
Section R.8.4.3) should be used, unless there is evidence (e.g., from a close analogue of the substance in question) of good correlation between the EC3 and human NOAEL/
LOAEL.
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NOAEL for the induction of respiratory sensitization in workers.
The NOAEL was adjusted to 1.8 ppb (i.e., 5 ppb  5/7  10/20) to
account for the difference in exposure frequency between working
(5 days/week) and sleeping (7 days/week) as well as the volume of
air inhaled performing 8 h of light to moderate work (10 m3) and
daily activities (20 m3) (USEPA, 2011b). The benchmark toxicity
value of 0.9 ppb (6400 ng/m3) for the induction of respiratory sen-
sitization in the general population was derived by dividing
1.8 ppb by a total uncertainty factor of 2 for intraspecies variability
(ECHA, 2010).
3.1.4. Respiratory tract effects – irritation and lung decrement not
related to asthma
While asthma is thought to be mediated by immunological
mechanisms, the respiratory tract irritation initiated by TDI ap-
pears to involve activation of the transient receptor potential
Ankyrin 1, an ion channel receptor located in sensory nerves lining
the airways (Taylor-Clark et al., 2009) which, in response to nox-
ious stimuli, mediates reﬂex respiratory responses including,
cough, rhinitis, bronchoconstriction, and neurogenic inﬂammation
(Jordt et al., 2004). These sensory mediated effects may lead to an
accelerated decline in pulmonary function. As no animal studies
could be found that distinguished between thresholds for asthma
and those for irritation and pulmonary function, the point of depar-
ture for these endpoints relies on epidemiology studies of worker
populations.
Studies by Henschler et al. (1962) in human volunteers reported
that acute exposures to TDI resulted in mild respiratory tract irri-
tation at 50 ppb TDI, but not at 20 ppb. Other investigators have re-
ported results of inhalation challenge tests in healthy volunteers as
well as persons with asthma or bronchial hyperreactivity (BHR)
with no known isocyanate exposure. Different exposure protocols
were used but, in general, TDI concentrations did not exceed
20 ppb. Baur (1985) reported mild irritation in healthy subjects
and more severe respiratory symptoms, cough and chest tightness,
in 4 of 15 asthmatics. Other studies detected no evidence of irrita-
tion, inﬂammatory response, or changes in forced expiratory vol-
ume (FEV) in subjects with bronchial hyperreactivity (BHR), innon-isocyanate asthmatics, or in healthy controls after TDI chal-
lenge (Chester et al., 1979; Fabbri et al., 1987; Moller et al.,
1986). In a study of 17 human volunteers without previous expo-
sures to isocyanates, 12 subjects exhibited moderate BHR after
exposure to TDI at 5 ppb for 6 h followed by a 20 min exposure
at 20 ppb. While none of the subjects had signiﬁcant respiratory
symptoms, some marginal changes in airway caliber and epithelial
permeability were found that were attributed to a possible phar-
macological effect. In conclusion, TDI concentrations of 20 ppb
for up to 30 min have not been found to produce notable effects
in healthy individuals. Persons diagnosed with non-TDI related
asthma or BHR have been found to be more sensitive to inhalation
exposures to TDI, experiencing symptoms and changes in speciﬁc
airway resistance at TDI concentrations of 10–20 ppb. It has been
noted that persons diagnosed with TDI-induced asthma can be
more sensitive, reacting to lower concentrations of TDI (O‘Brien
et al., 1979).
Acute bronchial irritation following exposure above the safe
occupational level can lead to inﬂammation and airﬂow limita-
tions, which are reversible. Such transient declines in lung function
across a working shift were observed in the earlier TDI literature
(Gandevia, 1963). It can be postulated that daily exposure sufﬁ-
cient to cause chronic lower airway inﬂammation or massive over-
exposure leading to airway remodeling can impair respiratory
function and lead to the permanent lung function decrement also
reported in the earlier literature (Adams, 1975; Holness et al.,
1984; Peters and Wegman, 1975; Wegman et al., 1974).
Two key indicators of pulmonary function employed in epide-
miological studies are the forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC). A large number of studies
focusing on pulmonary function have been conducted in TDI man-
ufacturing units as well as in foam production plants and spray
painting facilities. These have included both cross-sectional and
longitudinal studies. Occupational experience has demonstrated
that long-term exposures above 20 ppb may result in a signiﬁcant
decline in FEV1 and Peak Expiratory Flow Rate over time; whereas,
concentrations of 5 ppb and below seem to be safe against airway
function impairment and sensitization. Reports of respiratory ef-
fects observed between 5 and 20 ppb have been negative (Musk
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pulmonary function results from larger and more recent longitudi-
nal studies where the TWA TDI concentrations were 65 ppb, Ott
and co-workers (2002, 2003) concluded that ‘‘these studies do not
provide evidence of an accelerated rate of decline in FEV1 among
TDI-exposed employees’’. This conclusion is supported by the results
of a prospective study of 251 TDI polyurethane foam production
workers in the UK followed over a period of 17 years (Clark et al.,
2003). The decreases in FEV1 and FVC seen in this study were unre-
lated to TDI exposure level and were comparable to those mea-
sured in other populations not exposed to TDI. Consistent with
these observations, the German Commission for the Investigation
of Health Hazards of Chemical Compounds in the Work Area
(DFG, 2003) concluded that workplace exposures to TDI should
be limited to a TWA of 5 ppb (35  103 ng/m3) to prevent acceler-
ated deterioration of lung function in exposed workers.
For non-occupational settings, the US Environmental Protection
Agency (USEPA, 1995) calculated a ‘‘Reference Concentration’’
(RfC)2 for TDI using ﬁve years of worker exposure data reported by
Diem et al. (1982). In the Diem et al. (1982) study, workers were di-
vided into two groups, those with low and high cumulative expo-
sures to TDI. When comparing the two groups, the authors
reported a signiﬁcant decline in lung function among never smokers
in the high exposure group, but not among previous or current
smokers. Although offering no explanation for these discrepancies,
USEPA (1995) judged the TWA exposure (0.9 ppb TDI) of never
smokers in the low cumulative exposure group to be the study
NOAEL and the TWA exposure (1.9 ppb) for never smokers in the
high exposure group to be the LOAEL. EPA used the former value
as the basis for its RfC calculation. However, there are concerns that
0.9 ppb may be overly conservative. For example, Diem et al. (1982)
suggested that the effect observed in never smokers may be due to
the peak exposures, noting that TWA concentrations in the high
exposure group exceeded 5 ppb 15% of the time but only 2% of the
time in the low exposure group. Indeed, when the same worker data
were reviewed by Weill et al. (1981), it concluded that the time
spent above 20 ppb was well correlated with the annual decline in
pulmonary function. The association of pulmonary effects with high,
short-term peak exposures is consistent with the conclusion by
Diem et al. (1982) and by others in more recent literature reviews
(Ott et al., 2000; Ott, 2002; Ott et al., 2003) that an 8-h TWA of
5 ppb adequately protects against pulmonary lung function decre-
ments caused by TDI. Despite these concerns, the RfC of 70 ng/m3
(0.01 ppb) based on a general population NOAEL of 2000 ng/m3
(0.3 ppb) was conservatively selected as worst-case benchmark tox-
icity value for pulmonary irritation and decrements in lung function
in the general population.
3.1.5. Carcinogenicity
TDI is classiﬁed as a Group 2B carcinogen (possibly carcinogenic
to humans) by the International Agency for Research on Cancer
(IARC, 1999), as a Category 2 carcinogen (suspect human carcino-
gen) in the European Commission (1998), as reasonably antici-
pated to be a human carcinogen by the US National Toxicology
Program (NTP, 2011), and as an A4 carcinogen (not classiﬁable as
a human carcinogen) by the American Conference of Governmental
Industrial Hygienists (ACGIH, 2010). These classiﬁcations are based
on the increased tumor incidences observed by the NTP (1986)
when TDI in corn oil was administered directly into the stomach
of rodents by oral gavage. However, this study was ﬂawed both
technically (i.e., mishandling of the test material) and conceptually2 The RfC is deﬁned as ‘‘an estimate (with uncertainty spanning perhaps an order of
magnitude) of a daily inhalation exposure of the human population (including
sensitive subgroups) that is likely to be without an appreciable risk of deleterious
effects during a lifetime’’.(i.e., gavage exposures) resulting in the formation of toluene dia-
mine (TDA), a known animal carcinogen, both prior to and after
TDI administration (NTP, 1986; Appendix I; Dieter et al., 1990). Gi-
ven the qualitative similarity between the carcinogenic responses
seen in rodents exposed to TDI and TDA (NCI, 1979), the NTP (Diet-
er et al., 1990) concluded that the degradation of TDI to TDA could
explain the carcinogenic effects noted with TDI. Quantitative sup-
port for this conclusion comes from two studies. In the ﬁrst (Tim-
chalk et al., 1994), rats were gavaged with either 60 mg/kg TDI in
corn oil (same dose as used by NTP) or 3 mg/kg TDA. Urinary anal-
yses indicated that both produced comparable metabolic proﬁles
of free TDA, N-acetylated TDA, and TDI/TDA conjugates. This ﬁnd-
ing is consistent with about 5% of the TDI gavage dose (i.e., 3 mg/kg
of the 60 mg/kg TDI dose) being converted to TDA. In the second
(Sielken et al., in press), a statistical comparison of the carcinogenic
responses seen with TDI (NTP, 1986) and TDA (NCI, 1979) support
the conclusion that the carcinogenic responses to TDI are consis-
tent with 5% of the gavaged TDI being transformed to TDA either
before and/or after exposure. The NTP (Dieter et al., 1990) dis-
missed concerns over its ﬂawed study by stating that TDA would
be similarly formed if exposures occurred via inhalation. This mis-
conception persists in the scientiﬁc community despite data to the
contrary.
The reactivity of TDI and its propensity to form TDA is different
in pure aqueous versus complex biological systems. Whereas the
formation of ureas and polyureas is the predominant reaction
pathway in water at neutral pH, conjugation with biomolecules
dominates in complex biological systems (Day et al., 1997; Mor-
mann et al., 2006; Seel et al., 1999). The reactions of TDI in biolog-
ical systems can be inﬂuenced by the pH of the in vivo
environment. The pH neutral and macromolecule-rich environ-
ments associated with physiological exposures (i.e., inhalation,
dermal, buccal) to TDI favor conjugation with macromolecules
with no detectable free TDA (Mormann et al., 2006; Rosenberg
and Savolainen, 1985; Timchalk et al., 1994). In contrast, the intro-
duction of TDI directly into the acidic environment of the stomach
(i.e., bolus dose by gavage) favors the formation of free TDA, which
can be detected systemically (Jeffcoat, 1988; Kennedy and Brown,
1998; Timchalk et al., 1994). A testament to the inﬂuence of pH on
the conversion of TDI to TDA is the laboratory practice of using acid
hydrolyses to convert TDI/TDA conjugates in biological ﬂuids to
free TDA (Skarping et al., 1994). The in vivo conversion of TDI to
TDA and the subsequent induction of a carcinogenic response only
under aphysiological (i.e., gavage) exposure conditions is consis-
tent with the observations that (a) lifetime inhalation exposures
of rodents to TDI vapor at a maximum tolerated concentration of
150 ppb did not elicit a carcinogenic response (Löser, 1983; Owen,
1984), (b) free TDA was not detected in rats following a 6-h inha-
lation exposure to TDI vapor at 2 ppm (Timchalk et al., 1994), a
concentration 400-fold higher than the TDI TLV, (c) free TDA was
not detected in the urine of TDI exposed workers before subjection
to acid hydrolysis (Skarping et al., 1994), and (d) three epidemio-
logical studies with updates, representing the combined long-term
mortality experience of more than 17,000 PU foam production
workers, failed to ﬁnd an association between occupational expo-
sure to diisocyanates and an increased risk of cancer (Hagmar
et al., 1993a,b, updated by Mikoczy et al., 2004; Schnorr et al.,
1996; Sorahan and Pope, 1993, updated by Sorahan and Nichols,
2002).
The data summarized above indicate that potential physiologi-
cal exposures to TDI such as those reported here (i.e., inhalation
and dermal contact) likely result in the formation of conjugates
by the reaction of TDI with biological macromolecules (Brown
and Burkert, 2002; De Marzo et al., 2000; Lange et al., 1999;
Mráz et al., 1998, 2000; Ogawa et al., 2006; Valstar et al., 2004;
Wisnewski et al., 2006; Ye et al., 2006), with no detectable free
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ping et al., 1994; Timchalk et al., 1994). Since inhalation exposures
in rodents and humans are not associated with carcinogenic effects
and do not produce detectable levels of free TDA in either species,
the cancer risk posed by the inhalation of TDI is considered negli-
gible and is not further evaluated herein.
Although dermal contact with TDI is expected to result in the
formation of polyureas on the skin surface and conjugates between
TDI and skin macromolecules, long-term studies of dermally ap-
plied TDI have not been conducted. While acute exposure studies
in rats indicate a small fraction of dermally applied radiolabelled
TDI (0.9%) can reach the systemic circulation (Hoffmann et al.,
2010), it is unlikely to be in the form of free TDA (Rosenberg and
Savolainen, 1985). Given the classiﬁcation of TDI as a potential hu-
man carcinogen by some authoritative bodies, the following calcu-
lation was done with the conservative assumption that the TDI that
reaches the systemic circulation will be converted into TDA. The
following calculation of the excess cancer risk posed by dermal
exposures to TDI is based on this theoretical assumption and is
evaluated here by extrapolation to the only available tumor data,
the NTP gavage study.
Using tumor data from the TDI gavage study in rodents (Dieter
et al., 1990; NTP, 1986), the carcinogenic potency of TDI was calcu-
lated using the USEPA benchmark dose methodology (http://
www.epa.gov/ncea/bmds/dwnldu.html) version 2.2 and the LMS
cancer model incorporated in this software. CSF calculations were
performed on the tumor rates adjusted for intercurrent mortality.
While CSF calculations are frequently used for genotoxic (non-
threshold) carcinogens, this approach is used here as a health pro-
tective assumption and not to imply that TDI is genotoxic after der-
mal administration. CSF calculations were performed for all tumors
observed in rats and mice, and the CSF with the highest unit risk
was conservatively selected to represent the carcinogenic potency
of TDI. The representative CSF (1.7  108 per ng TDI/kg bw/day)
was derived from combined ﬁbroma and ﬁbrosarcomas in the male
rat. This tumor type may be relevant for dermal exposures. The
dosages were 0, 30 or 60 mg/kg bw/day administered 5 days per
week. The CSF was adjusted using a rat to human allometric scaling
factor of 4, and a correction factor of 7 days/5 days (continuous
exposure) (ECHA, 2010) and subsequently divided by the gastroin-
testinal absorption efﬁciency of TDI (20%; Timchalk et al., 1994) to
yield a ﬁnal CSF of 4.8  107 per ng TDI/kg bw/day.
3.2. Exposure characterization
This assessment determines the amount of TDI monomer that
might migrate or be emitted from PU foam based on the results
of a novel set of studies described by Vangronsveld et al. (2012).
These studies do not rely on solvent extraction of PU polymers that
can result in chemical degradation of the polymer and the release
of molecules bound in the polymer matrix. The TDI levels mea-
sured by Vangronsveld et al. (2012) were subsequently combined
with conservative (health protective) exposure factors (e.g., inhala-
tion rate, contact area, exposure duration and frequency) to deter-
mine upper-bound dermal and inhalation exposure values (for
non-cancer endpoints) and the LADD (for the cancer endpoint)
associated with sleeping on a ﬂexible PU foam mattress.
3.2.1. Skin irritation, sensitization and LADD
TDI was not detected migrating from foam with a method
detection limit (MDL) of 0.16 ng TDI (combined isomers)/cm2 of
foam surface area. Based on one-half the MDL, the mass of TDI as-
sumed contacting the skin for the assessment of irritation and sen-
sitization was 0.08 ng TDI/cm2. Since the LADD is based on a
lifetime exposure, three age groups were considered: <2 years of
age, 2 to <16 years of age, and 16–70 years of age (USEPA, 2005).The LADD (i.e., potential internal dose of TDI) was calculated by
combining the external dose to the skin (0.08 ng TDI/cm2), an 8-
h dermal absorption value for 2,4-TDI in rat skin of 0.9% (Hoffmann
et al., 2010), and age-speciﬁc variables as outlined in Table 2. The
calculated LADD likely overestimates any potential exposure since
human skin is generally recognized as being 3-fold to 10-fold less
permeable to chemicals than rat skin and since the PU mattress
and much of the skin would typically be covered by fabric which
would impede TDI migration and thereby reducing the extent of
any exposure.
3.2.2. Respiratory tract sensitization and lung decrement
TDI was not detected in emissions from PU ﬂexible foam (Vang-
ronsveld et al., 2012). MDLs of 0.003 ng/cm2 and 0.002 ng/cm2
were reported for 2,4-TDI and 2,6-TDI, respectively. Summing
these values gives an estimated minimum detectable total TDI
emission rate of 0.005 ng/cm2 (50 ng TDI emitted/m2 of foam).
An upper-bound air concentration (2.2 ng TDI/m3) was determined
based on an emission rate of 25 ng TDI/m2 (i.e., one-half the MDL;
USEPA, 1989) and the assumptions in Table 3. This concentration
was reduced to an effective upper-bound concentration of
0.44 ng TDI/m3 (2.2 ng TDI/m3  4 m3/20 m3) to account for the
fact that the toxicity benchmark is based on the 20 m3 of air in-




The MOSs for the non-cancer endpoints ranged from 200 to 3
million, well above the target MOS of 1 (Table 4). As indicated ear-
lier in Section 3.1.2, estimates of dermal sensitization threshold
determined from experimental animal studies and that from the
workplace experience do not provide a consistent proﬁle of po-
tency since dermal sensitization is rare in humans. Regardless, a
conservative NESIL was calculated based upon animal data. There-
fore, skin irritation, skin sensitization, respiratory sensitization and
lung decrement effects from potential dermal and inhalation expo-
sures to TDI while sleeping on a mattress poses a negligible non-
cancer risk.
3.3.2. Cancer endpoints
The modelled lifetime exposure to sleeping on a PU foam mat-
tress was combined with the CSF and conservative age-dependent
adjustment factors of 10 and 3 (for <2 years of age and 2–16 years
of age, respectively) to yield a total excess cancer risk of 1  107,
which is 10-fold lower than the lower boundary of the typical ex-
cess cancer risk range (1  106 to 1  104) targeted by regulatory
agencies. This conservative excess cancer risk is calculated using a
CSF derived from a technically and conceptually ﬂawed TDI gavage
study that resulted in the production of TDA, a known rodent car-
cinogen, and ignores the observation that TDI is not carcinogenic
by inhalation, the typical exposure route in humans (Section 3.1.5).4. Discussion
A risk assessment framework for the evaluation of TDI-derived
PU products was developed to evaluate the potential consumer
health risks associated with ‘‘sleeping on a ﬂexible PU foam mat-
tress.’’ While this scenario is thought to represent a situation
accentuating potential consumer exposure to PU foam (and thus
TDI if present), additional exposures can also be hypothesized.
Although no evidence exists to suggest such exposure, TDI emis-
sions from PU carpet underlayment could contribute to the inhala-
tion exposure, although migration of TDI would not affect dermal
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precluded. Such additional sources of theoretical exposure to TDI
were not included in this assessment; however, sufﬁcient informa-
tion is presented herein to adjust the estimated risks for more
complex exposure scenarios. For the assessment, toxicity bench-
marks for TDI relevant endpoints were combined with migration
and emission data from a TDI-based PU ﬂexible foam commonly
used in bedding. The results from the emission and migration tests
showed no detectable TDI. Therefore, for the purposes of deriving a
measure of emission rate from this foam sample, non-detectable
results were assigned a numeric value of 50% of the respective
MDLs.
Human data are preferred for the identiﬁcation of benchmark
toxicity values. However, the occurrence of skin irritation and
allergic contact dermatitis in workers has been reported only
rarely. Therefore, toxicity benchmarks for these endpoints were
based on data in animals. An important aspect of the animal data
used for these benchmarks is that they demonstrate a dose
(threshold) belowwhich skin irritation and sensitization do not ap-
pear to occur (Selgrade et al., 2006) and in principle this conclusion
is considered applicable to humans as well. However, the thresh-
olds derived from animal experiments appear to be lower than
those of humans, based on limited occurrences reported after sev-
eral decades of workplace experience. This discordance is particu-
larly evident for skin sensitization where occupational experience
shows that TDI (and indeed other diisocyanates) are relatively
weak inducers of allergic contact dermatitis while the mouse LLNA
indicates TDI is a strong skin sensitizer (ECETOC, 2008). Thus, the
effect levels for skin irritation and sensitization derived in this
assessment are conservative relative to human effect levels. It is
beyond the scope of this assessment to resolve these apparent dis-
crepancies, but there appears to be a need to elucidate the differ-
ence in mechanism of dermal sensitization between the rodent
sensitization assays (mouse LLNA, GPMT) and human allergic der-
matitis. Until further clarity is achieved, the derived threshold for
dermal sensitization should be used with caution for human risk
assessment. There appears to be less of a discrepancy for dermal
irritation to TDI. The toxicity benchmarks used herein should be
re-assessed as new scientiﬁc information for TDI becomes available
and modiﬁed as appropriate.Table 2








TDI concentration available for dermal
exposure per event
0.08 0.08 0.08
Body surface area in contact with foam 3050 10,300 12,800
Percent dermal absorption 0.9% 0.9% 0.9%
Body weight 11.4 56.8 80
Events per day 1 1 1
Average daily dose 0.19 0.13 0.12
Days exposed 365 365 365
Years exposed 2 13 55
Years in a lifetime 70 70 70
LADDa 0.0055 0.024 0.091
Cancer slope factor (CSF) 4.8  107 4.8  107 4.8  107
Age dependent adjustment factor 10 3 1
Population cancer riskb 2.6  108 3.5  108 4.3  108
Total cancer risk 1.0  107
a LADD ¼
TDI conc:






b Population cancer risk = CSF  Age dependent adjustment factor  LADD.Respiratory sensitization and decrements in lung function are
the primary adverse health effects associated with TDI. While the
threshold for induction of TDI-asthma has not been empirically
determined for humans (Ott, 2002), they have been characterized
in animals (Karol, 1983). The downward trend in recent years in
the incidence of diisocyanate occupational asthma (Vandenplas
et al., 2011; Buyantseva et al., 2011; Paris et al., 2012) supports re-
sults from animal models indicating that the respiratory sensitiza-
tion and lung function decrements produced by diisocyanates are
threshold events and that current occupational exposure guide-
lines adequately protect against both. Methodologies for assessing
thresholds for respiratory effects in humans continue to evolve.
Advances in this ﬁeld have been particularly difﬁcult due to the
complexity of sensitization and the factors that contribute to the
development of allergic disease (see Table 1). While some aspects
of sensitization can be quantitatively addressed (e.g., occlusion,
product use), other factors like biological and genetic variation,
allergic susceptibility, mechanisms of chemical allergy remain a
challenge.
Studies of workers have not reported carcinogenic effects re-
lated to TDI exposure; these observations are consistent with the
absence of tumors in rats and mice exposed to TDI vapor for a life-
time. For these reasons, the cancer risk posed by the inhalation of
TDI was not considered in this assessment. However, because reg-
ulatory agencies continue to classify TDI as a potential human car-
cinogen based on a ﬂawed study in which rodents were
administered TDI by gavage, this assessment used these studies
to consider the unlikely possibility that dermal exposures to TDI
will cause cancer in humans. As suggested by the gavage study
authors (Dieter et al., 1990) and supported by subsequent analyses
(Sielken et al., in press), the tumors likely resulted from the conver-
sion of a small amount of TDI to TDA (a known animal carcinogen)
due to improper test sample handling and the aphysiological expo-
sure conditions associated with the study protocol. TDI in contact
with the skin is unlikely to be converted to TDA since the relatively
pH-neutral conditions at and below the skin surface favor the for-
mation of polyureas and conjugation of TDI with macromolecular
components of the stratum corneum. Thus, the excess cancer risk
calculated via this exposure route will overestimate the real risk,
if any.ial cancer risk for dermal exposure of TDI derived from sleeping on a ﬂexible foam
rs Unit References
ng/cm2-event Section 3.2.1
cm2 USEPA, 2011b, one-half the 95th percentile value for
children aged 1 to <2 years, 11 to <16 years, and adult
males aged 40 to <50 years
percent Hoffmann et al. (2010)
kg USEPA, 2011b, mean body weight for children aged 1 to
<2 years, 11 to <16 years, and adults






(ng/kg-day)1 Calculated, Section 3.1.5, from oral gavage data
USEPA, 2005
Calculated
Calculated, the sum of all three age groups
Table 3
Assumptions for the determination of the TDI inhalation exposure concentration.
Parameter Value Unit Notes
Estimated amount of TDI emitted per area 25a ng/m2 Vangronsveld et al. 2012, emission per 8 h
Surface area of mattress 10.4b m2 calculated
Total amount of TDI released from foam mattress 260 ng 10.4 m2  25 ng/m2
Volume of roomc 30 m3
Air exchanges per 8 h 4 # 0.5 exchanges per hour, USEPA, 2011b
Concentration of TDI in bedroom air 2.2 ng/m3 260 ng/(30 m3 x 4)
Adjustment for breathing rate while sleeping 0.2 – 4 m3/day breathing rate during 8 h of sleep (USEPA, 2011b)
divided by standard breathing rate of 20 m3/day
Inhalation exposure concentration 0.44 ng/m3 2.2 ng/m3  0.2
a The results from the emission tests showed no detectable TDI. Therefore, for the purposes of deriving a measure of emission rate from this foam sample, non-detectable
results were assigned a numeric value of 50% MDL for the cell type used in the method with the highest sensitivity used for the emission testing.
b The surface area (m2) of all sides of a king sized mattress [2 m (length)  2 m (width)  0.3 m (depth)] was determined.
c The deﬁnition of a ‘‘standard’’ room size for a bedroom varies widely (e.g. from 16 m3 to 41 m3) in European risk assessment (European Chemicals Bureau, 2003) and
Jennings et al. (1987) guidance respectively. For this assessment a room volume of 30 m3 is used, based upon the large size mattress used would likely be in a relatively larger
size bedroom.
Table 4










Skin irritation Human LOAEL 600,000 ng/
cm2
3 200,000 ng/cm2 0.08 ng/cm2 3  106





12,800 ng/m3 2 6400 ng/m3 0.44 ng/m3 15,000
Respiratory tract effects (lung decrement) Human occupational
NOAEL
2000 ng/m3 30 70 ng/m3 0.44 ng/m3 200
LOAEL = Lowest observable adverse effect level.
EC3 = the concentration leading to a threefold increase of the baseline lymph node cell proliferation in the LLNA.
(Local Lymph Node Assay) using thymidine labeling (Kimber et al., 2001).
NOAEL = No observable adverse effect level.
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data from emission and migration studies to estimate TDI expo-
sures via inhalation and dermal contact, respectively. Data ob-
tained from these studies were judged a better reﬂection of the
physiological conditions associated with human exposures to PU
foam than solvent-based extraction procedures that can catalyze
the decomposition of TDI-based polymers in PU foam to produce
TDI (Vangronsveld et al., 2012). During the design of the migration
studies, consideration was given to using artiﬁcial sweat as a sol-
vent to mimic the environment of the human skin surface. How-
ever, this procedure was deemed inappropriate since it might
have resulted in an underestimate of migration due to the low sol-
ubility of TDI monomer in aqueous solutions and its transforma-
tion into polyureas. Instead, Vangronsveld et al. (2012) used a
solid matrix coated with a diisocyanate derivatizing agent to quan-
titate directly the presence of TDI migrating to the foam surface
without the potential limitations of intervening media.
Several conservative (health protective) exposure assumptions
were incorporated into this risk assessment. The modeled expo-
sure scenario used a large mattress relative to the size of the room,
an assumption that increases potential inhalation exposures to TDI.
Furthermore, although unrealistic, it was assumed there were no
intervening fabrics (e.g., mattress cover, clothing) that would nor-
mally limit dermal exposures to a reactive chemical like TDI. In
addition, it was assumed that individuals would always sleep on
a PU foam mattress and that the mattress was an inﬁnite source
of free TDI even though these levels, if present, would be expected
to decrease over time. A potential non-conservative assumption
was the 8 h sleep period, which is consistent with the time course
of the emission (i.e., 8 h) and migration (i.e., 8 and 24 h) analyticalstudies. Adjustment was not made for additional time one might
spent on the mattress since kinetic data were not available due
to the absence of detectable TDI levels in both studies. However,
even a doubling of sleep time (i.e., risk) from 8 to 16 h would not
affect our conclusions given the range in MOSs listed in Table 4
(200 to 3  106).5. Conclusion
A quantitative risk assessment for consumer exposure to TDI
while sleeping on a ﬂexible PU foam mattress is developed that
is based on a careful consideration of the toxicological properties
of TDI, results from migration and emission studies from a foam
typically used for ﬂexible PU mattresses, and conservative expo-
sure assumptions. We conclude from this assessment that sleeping
on a PU foam mattress for a lifetime does not pose TDI-related
health risks to consumers. Using this framework, similar risk eval-
uations can be developed for other PU products or applications
based on the toxicity information, appropriate analytical data,
and exposure modelling approaches speciﬁc to the application.Conﬂict of interest statement
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